scholarly article | Q13442814 |
P356 | DOI | 10.1016/S1474-4422(18)30412-5 |
P698 | PubMed publication ID | 30563684 |
P50 | author | Ettore Beghi | Q47264144 |
Giorgia Giussani | Q47710160 | ||
P2860 | cites work | Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study | Q30540714 |
Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug | Q38665970 | ||
Treatment Outcomes in Patients with Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study | Q47245856 | ||
Mortality in Dravet syndrome | Q47888090 | ||
Cannabinoids for epilepsy: What do we know and where do we go? | Q48162585 | ||
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial | Q50109024 | ||
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. | Q52655447 | ||
Heart rate variability in epilepsy: A potential biomarker of sudden unexpected death in epilepsy risk | Q58831398 | ||
Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry | Q61849442 | ||
Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome | Q62868130 | ||
P433 | issue | 1 | |
P304 | page(s) | 7-8 | |
P577 | publication date | 2019-01-01 | |
P1433 | published in | Lancet Neurology | Q15755067 |
P1476 | title | Treatment of epilepsy in light of the most recent advances | |
P478 | volume | 18 |